Incretin Atlas › Molecules › Lenbelintide
Lenbelintide
Amylin · s.c. · AstraZeneca
Summary
- Also known as
- AZD6234, AstraZeneca
- Mechanism
- Amylin
- Route
- s.c.
- Company
- AstraZeneca
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 recruiting (adjunct to incretin-based therapy, 68 weeks) verify
- Next milestone
- Phase 3 readout
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Phase 3 recruiting: adjunct to incretin-based therapy, 68 weeks | AZD6234 phase 3 |
| T2D | 0 no data | ||
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Registered trials (4)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| SELENE-Asia A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes | Obesity | Phase 3 | not yet recruiting | 2027-01 → 2028-09 | 330 | not yet recruiting | NCT07922330 |
| SELENE 3 A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus | Obesity | Phase 3 | recruiting | 2026-08 → 2028-08 | 500 | recruiting | NCT07776509 |
| SELENE 2 A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight | Obesity | Phase 3 | recruiting | 2026-08 → 2028-08 | 1500 | recruiting | NCT07784270 |
| SELENE 1 A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus | Obesity | Phase 3 | recruiting | 2026-08 → 2028-08 | 2500 | recruiting | NCT07784725 |
Primary sources
No source recorded.
How to cite this page
Medical Adviser's Group. Incretin Atlas: Lenbelintide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/lenbelintide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.